MIST Stock Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
Milestone Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.07|
|52 Week High||US$9.85|
|52 Week Low||US$3.98|
|1 Month Change||4.61%|
|3 Month Change||49.42%|
|1 Year Change||55.04%|
|3 Year Change||-50.33%|
|5 Year Change||n/a|
|Change since IPO||-40.99%|
Recent News & Updates
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|MIST||US Pharmaceuticals||US Market|
Return vs Industry: MIST exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: MIST exceeded the US Market which returned -23.2% over the past year.
|MIST Average Weekly Movement||9.4%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: MIST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MIST's weekly volatility (9%) has been stable over the past year.
About the Company
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.
Milestone Pharmaceuticals Fundamentals Summary
|MIST fundamental statistics|
Is MIST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MIST income statement (TTM)|
|Cost of Revenue||US$1.40m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.06|
|Net Profit Margin||0.00%|
How did MIST perform over the long term?See historical performance and comparison
Is MIST undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MIST?
Other financial metrics that can be useful for relative valuation.
|What is MIST's n/a Ratio?|
Price to Book Ratio vs Peers
How does MIST's PB Ratio compare to its peers?
|MIST PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
JUSH.F Jushi Holdings
XERS Xeris Biopharma Holdings
OCUL Ocular Therapeutix
PRPH ProPhase Labs
MIST Milestone Pharmaceuticals
Price-To-Book vs Peers: MIST is expensive based on its Price-To-Book Ratio (3.1x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does MIST's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: MIST is expensive based on its Price-To-Book Ratio (3.1x) compared to the US Pharmaceuticals industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is MIST's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate MIST's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MIST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MIST's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MIST's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Milestone Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MIST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MIST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MIST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MIST is forecast to have no revenue next year.
High Growth Revenue: MIST is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MIST's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Milestone Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MIST is currently unprofitable.
Growing Profit Margin: MIST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MIST is unprofitable, and losses have increased over the past 5 years at a rate of 14.2% per year.
Accelerating Growth: Unable to compare MIST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: MIST has a negative Return on Equity (-71.27%), as it is currently unprofitable.
Discover strong past performing companies
How is Milestone Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MIST's short term assets ($90.5M) exceed its short term liabilities ($4.3M).
Long Term Liabilities: MIST's short term assets ($90.5M) exceed its long term liabilities ($384.0K).
Debt to Equity History and Analysis
Debt Level: MIST is debt free.
Reducing Debt: MIST has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MIST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MIST has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 10% each year.
Discover healthy companies
What is Milestone Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Milestone Pharmaceuticals Dividend Yield vs Market|
|Company (Milestone Pharmaceuticals)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Milestone Pharmaceuticals)||n/a|
Notable Dividend: Unable to evaluate MIST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MIST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MIST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MIST's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MIST has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Oliveto (54 yo)
Mr. Joseph G. Oliveto, also known as Joe, M.B.A., has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and has been its Director since July 2017. Mr. Oliveto served a...
CEO Compensation Analysis
|Joe Oliveto's Compensation vs Milestone Pharmaceuticals Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$4m||US$509k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$4m||US$470k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$785k||US$458k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$1m||US$360k|
|Dec 31 2017||US$851k||US$364k|
Compensation vs Market: Joe's total compensation ($USD4.10M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
Experienced Management: MIST's management team is considered experienced (2.7 years average tenure).
Experienced Board: MIST's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|23 Sep 22||BuyUS$3,948,910||Novo Holdings A/S||Company||432,290||US$9.60|
|07 Sep 22||BuyUS$13,564,484||RTW Investments, LP||Company||1,557,346||US$8.71|
|07 Sep 22||SellUS$13,564,484||RTW Investments, LP||Company||1,557,346||US$8.71|
|31 May 22||BuyUS$28,000||Paul Truex||Individual||5,000||US$5.60|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Milestone Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Milestone Pharmaceuticals Inc.
- Ticker: MIST
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$272.199m
- Shares outstanding: 30.01m
- Website: https://www.milestonepharma.com
Number of Employees
- Milestone Pharmaceuticals Inc.
- 1111 Dr. Frederik-Philips Boulevard
- Suite 420
- H4M 2X6
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MIST||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||May 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.